title: Clinical and Preclinical Use of LOX-1-Specific Antibodies in Diagnostics and Therapeutics.
abstract: Lectin-like oxidized low-density lipoprotein receptor-1 (SR-E1, LOX-1, OLR1) was first discovered as a vascular receptor for modified lipoprotein particles nearly 20 years ago. Since then, in vitro and in vivo studies have demonstrated an association between LOX-1, a soluble form (sLOX-1) and a number of diseases including atherosclerosis, arthritis, hypertension and pre-eclampsia. However, converting such discoveries into tools and drugs for routine clinical use is dependent on translational preclinical and clinical studies but such studies have only begun to emerge in the past decade. In this review, we identify the key clinical applications and corresponding criteria that need to be addressed for the effective use of LOX-1-related probes and molecules for patient benefit in different disease states.
authors.affiliation: Endothelial Cell Biology Unit, School of Molecular and Cellular Biology, University of Leeds, Leeds, LS2 9JT, UK. ugm3jrds@leeds.ac.uk.|Leeds Vascular Institute, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK. ugm3jrds@leeds.ac.uk.
authors.forename: Jonathan
authors.initials: J
authors.lastname: De Siqueira
authors.affiliation: Endothelial Cell Biology Unit, School of Molecular and Cellular Biology, University of Leeds, Leeds, LS2 9JT, UK.
authors.forename: Izma
authors.initials: I
authors.lastname: Abdul Zani
authors.affiliation: Leeds Vascular Institute, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK.|Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, LS2 9JT, UK.
authors.forename: David A
authors.initials: DA
authors.lastname: Russell
authors.affiliation: Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, LS2 9JT, UK.
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Wheatcroft
authors.affiliation: Endothelial Cell Biology Unit, School of Molecular and Cellular Biology, University of Leeds, Leeds, LS2 9JT, UK.
authors.forename: Sreenivasan
authors.initials: S
authors.lastname: Ponnambalam
authors.affiliation: Endothelial Cell Biology Unit, School of Molecular and Cellular Biology, University of Leeds, Leeds, LS2 9JT, UK.|Leeds Vascular Institute, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK.
authors.forename: Shervanthi
authors.initials: S
authors.lastname: Homer-Vanniasinkam
mesh_terms: D000818:Animals; D000906:Antibodies / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D000918:Antibody Specificity; D002317:Cardiovascular Agents / Q000276:immunology / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000175:diagnosis* / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D015195:Drug Design; D000939:Epitopes; D006801:Humans; D007158:Immunologic Techniques; D058990:Molecular Targeted Therapy; D011237:Predictive Value of Tests; D051127:Scavenger Receptors, Class E / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D015398:Signal Transduction; D057170:Translational Research, Biomedical / Q000379:methods*
chemical_list: D000906:Antibodies; D002317:Cardiovascular Agents; D000939:Epitopes; C495137:OLR1 protein, human; D051127:Scavenger Receptors, Class E
keywords: Atherosclerosis; Biomarker; LOX-1; Oxidized LDL; Scavenger receptor